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Abstract: Community-acquired pneumonia (CAP) is the cause of substantial morbidity, mortality, 
and resource utilization worldwide. When choosing an antimicrobial, effective treatment depends 
on proper patient evaluation and the identiﬁ  cation of numerous risk factors, such as recent anti-
biotic exposure or the presence of comorbidity. Patients without any risk factor should be treated 
effectively with a narrow spectrum β-lactam agent, like amoxicillin, or a macrolide. If a risk 
factor is present, agents with a broader spectrum of activity should be selected for the empirical 
therapy. The newer-generation quinolones are suitable agents with their excellent in vitro activity 
and pharmacodynamic–pharmacokinetic properties. They are not only active against susceptible 
CAP pathogens, but also against the resistant strains. Among the quinolones, gemiﬂ  oxacin has the 
best in vitro activity. Its improved bioavailability, pharmacokinetic–pharmacodynamic properties, 
and safety proﬁ  le make this agent an excellent option for the treatment of CAP. 
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Introduction
Community-acquired pneumonia (CAP) remains a frequent and important clinical 
entity. Each year, there are 2 to 3 million cases of CAP in the US, resulting in approxi-
mately 10 million physician visits (Bartlett et al 2000). Despite substantial progress 
in therapeutic options, CAP remains a signiﬁ  cant cause of morbidity and death, and 
there continue to be major controversies concerning the antimicrobial management 
of this infection (Paganin et al 2004). The mixed etiology and the changing suscep-
tibility of pathogens causing CAP, in particular that of Streptococcus pneumoniae, 
has created a challenge, in some circumstances, to clinicians as to which therapeutic 
approaches may be the most appropriate in terms of optimal patient outcome (Oncu 
et al 2005). Initial antimicrobial therapy is normally given empirically, before the 
bacterial cause of the infection can be determined in the laboratory, and in many cases 
treatment is empirical throughout due to the lack of reliable microbiological data. An 
understanding of the possible pathogens and resistance patterns is helpful in guiding 
antibiotic choice, and a detailed knowledge of the local susceptibility of the potential 
pathogens would ensure a more appropriate selection of the antimicrobial agent to be 
used (Appelbaum et al 2004). This review focuses on the treatment options of CAP 
with special emphasis on gemiﬂ  oxacin. 
Etiology of CAP
Although CAP may be caused by many possible pathogens, a limited number of com-
mon pathogens are responsible for most cases (Lim et al 2001). In fact, no etiologic 
agent is found in as many as 50% of cases, even when extensive diagnostic testing 
is performed (Niederman et al 2001). In those cases in which an etiologic agent is 
identiﬁ  ed, S. pneumoniae accounts for the majority of bacterial pneumonia (Jokinen Therapeutics and Clinical Risk Management 2007:3(3) 442
Öncü 
et al 2001). Relative to other pathogens, Mycoplasma pneu-
moniae, Chlamydia pneumoniae, Haemophilus inﬂ  uenzae, 
Legionella pneumophila, and respiratory viruses are also 
common.
Staphylococcus aureus and Enterobacteriaceae pathogens 
are found in a selected group of patients such as those who 
have had inﬂ  uenza, have previously taken antimicrobial 
drugs, or have comorbidities (Arancibia et al 2002). Table 1 
lists the most common pathogens associated with CAP based 
on the collective results of recent studies and based on the 
severity of illness as judged by the site of care (outpatient 
versus inpatient) (File 2003; File and Niederman 2004).
Of the respiratory pathogens, penicillin-resistant S. pneu-
moniae (PRSP) has attracted the greatest interest. PRSP is a 
widespread problem, with rates of resistance ranging from 
5% to 80% in various parts of the world (Forward 1999; 
Oncu et al 2005). Risk factors for infection with PRSP 
strains include young age, day-care center attendance, prior 
administration of antimicrobial agents, and severe underly-
ing diseases (Clavo-Sanchez et al 1997). As the use of non-
penicillin antimicrobials has increased, so has the develop-
ment of resistance to these agents among S. pneumoniae. 
Worldwide rate of macrolide resistance has risen dramatically 
in recent years. The prevalence of resistance is highly variable 
between countries, ranging from <3% to >70% (Cizman et al 
1999; Oster et al 1999). Emergence of S. pneumoniae with 
reduced susceptibility to quinolones has also been reported 
in England and the US (Brueggemann et al 2002; Johnson 
et al 2003). Fortunately, the incidence of quinolone resistance 
is currently low worldwide (<1%) (Garcia-Rodriguez and 
Munoz Bellido 2000). 
Outpatient vs inpatient treatment
A clinical prediction rule has been tested based upon the 
likelihood of mortality from CAP (Fine et al 1997; Lim et al 
2003). It is especially useful to predict the severity of CAP, 
to identify patients who can be safely treated as outpatients 
(Figure 1) (Lim et al 2003). Prediction of the severity of 
CAP is also used to estimate the possible etiology of CAP 
and guides the selection of empirical therapy. The approach 
to empirical antimicrobial drug selection in CAP is presented 
in Figure 2. 
Antimicrobial therapy
Ideally, the choice of antibacterial therapy for the empirical 
treatment of CAP will be one that is highly effective against 
the common respiratory pathogens, in particular S. pneu-
moniae, has a good safety proﬁ  le with few adverse effects, 
and is formulated to achieve adequate dosing to eradicate 
the infecting pathogen.
β-lactam antibiotics
The relationship between the inappropriate use of antimi-
crobials and resistance might suggest that β-lactams would 
have reduced effectiveness in CAP caused by S. pneumoniae. 
Although this is the case for meningeal infections, the clini-
cal relevance of resistance in the treatment of pneumonia 
remains controversial. Several studies have shown no dif-
ference in outcomes, including mortality, between patients 
with penicillin-susceptible and those with penicillin-resistant 
S. pneumoniae as the cause of CAP (Friedland 1995; Pallares 
et al 1995; Choi and Lee 1998; Deeks et al 1999). It is likely 
that, in cases in which isolates have intermediate or low-level 
resistance to penicillin, the drug concentrations achieved 
in serum and in the lungs are adequate to eradicate these 
strains. However, strains for which the minimum inhibitory 
concentrations (MICs) of penicillin are higher (≥4 mg/L) may 
affect outcomes, and therapeutic failures are more likely to 
be seen as more strains with high-level penicillin resistance 
emerge (Pallares et al 2003). Although the impact of PRSP 
in CAP has been evaluated in several studies, the impact of 
cephalosporin resistance is less well studied. Several studies 
reported that cephalosporin resistance negatively affected the 
clinical outcomes of patients with CAP (Ailani et al 2002; 
Yu et al 2003; Garau 2005). In pneumonia caused by other 
respiratory pathogens, such as H. inﬂ  uenzae and Moraxella 
catarrhalis, the impact of resistance caused by β-lactamase 
production can be overcome by the use of a β-lactam/β-
lactamase inhibitor combination or a β-lactamase-stable 
cephalosporin (Garau 2005).
Macrolides
Although the global increase in macrolide resistance in 
isolates of S. pneumoniae is disturbing, the clinical impact 
Table 1 Microbiological etiology in CAP by site of care
CAP in primary care  CAP requiring hospitalization
S. pneumoniae  S. pneumoniae
M. pneumoniae  H. inﬂ  uenzae
C. pneumoniae  M. pneumoniae
H. inﬂ  uenzae  C. pneumoniae
M. catarrhalis  M. catarrhalis
Respiratory viruses  Legionella spp.
  S. aureus
 Enterobacteriaceae  species
 Respiratory  virusesTherapeutics and Clinical Risk Management 2007:3(3) 443
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of these in vitro results has not been determined (Gotfried 
2000). In vitro macrolide resistance may not translate into 
therapeutic failure if high tissue concentrations are achieved 
at the site of infection. This may be the case for infections 
caused by strains of S. pneumoniae with low-level macrolide 
resistance (MIC <8 µg/mL) through increased active efﬂ  ux 
of antimicrobials (Shortridge et al 1999). On the other hand, 
the majority of pneumococci harboring the ermB gene ex-
hibit high levels of resistance that cannot be overcome by 
clinical use of macrolides; therefore, failure is predictable 
if a macrolide is used in infections caused by strains harbor-
ing the ermB gene (Oster et al 1999). Several studies have 
examined macrolides in the treatment of CAP in outpatients 
who were subsequently hospitalized (Kelley et al 2000; 
Lonks et al 2002; Van Kerkhoven et al 2003). The results of 
these studies suggest that breakthrough bacteremia is likely 
to occur during macrolide therapy for pneumonia due to the 
presence of macrolide-resistant S. pneumoniae strains. In 
addition, there have been several case reports and case series 
concerning macrolide failures in patients with pneumonia 
caused by macrolide-resistant strains (Fogarty et al 2000; 
Kelley et al 2000; Musher et al 2002). 
Based on current rates and level of macrolide resis-
tance, continued use of this drug class is warranted for 
most patients with CAP. A macrolide alone should be an 
adequate treatment option for mild-to-moderate CAP in 
patients who have been healthy and are without risk fac-
tors for antibiotic resistance (recent macrolide use, age <5 
or >65 years, daycare attendance, recent hospitalization, 
residence in a high prevalence area). Given the inability 
0-1
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2
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≥3
Severe
Any of: 
•Confusion
•Respiratory rate ≥ 30/min 
•Urea >7 mmol/L
•Hypotension (SBP <90 mmHg, DBP ≤60 mmHg)
•Age ≥ 65 
Outpatient
management
Consider hospital
management
Manage in hospital
Figure 1 Prediction of the severity of CAP and recommendation for patient site of management.Therapeutics and Clinical Risk Management 2007:3(3) 444
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to predict antibiotic resistance, however, macrolides are 
not recommended for the treatment of complicated or life- 
threatening severe CAP.
Quinolones
Quinolones inhibit bacterial DNA gyrase and topoisom-
erase IV, thereby causing bacterial cell death (Lewis et al 
1996; O’Donnell and Gelone 2000). Topoisomerase IV is a 
key target for quinolones that have activity against Gram-
positive organisms (O’Donnell and Gelone 2000). The early 
quinolones, ciproﬂ  oxacin and oﬂ  oxacin, are not considered 
suitable for the treatment of CAP because of their low activ-
ity against Gram-positive bacteria (O’Donnell and Gelone 
2000). Recent years have seen the development of newer 
quinolones such as levoﬂ  oxacin, gatiﬂ  oxacin, moxiﬂ  oxacin, 
and gemiﬂ  oxacin, which have signiﬁ  cantly improved activ-
ity against Gram-positive organisms (including PRSP) and 
macrolide-resistant strains (Garcia-Rodriguez and Munoz 
Bellido 2000). These agents have enhanced activity against 
topoisomerase IV. They have rapid bactericidal activity 
and desirable pharmacokinetic and pharmacodynamic fea-
tures (Garcia-Rodriguez and Munoz Bellido 2000). These 
newer quinolones are also active against bacteria causing 
atypical pneumonia and against β-lactamase producing and 
non-producing H. inﬂ  uenzae and M. catarrhalis. Moreover, 
they have a good activity against other other Gram-negative 
bacilli, similar or even higher, in some cases, to ciproﬂ  oxacin. 
Current resistance is very low in these agents and so, from a 
theoretical point of view, their spectrum and intrinsic activity 
are suitable for the treatment of CAP. 
Gemiﬂ  oxacin
Gemiﬂ  oxacin was approved by the FDA in 2003 to treat 
mild-to-moderate CAP caused by a range of pathogens. It is 
a ﬂ  uoronaphthyridone possessing a C-7 pyrrolidine substi-
tution. The commercially available product is gemiﬂ  oxacin 
mesylate salt in the sesquihydrate form. Gemiﬂ  oxacin is 
available in tablet formulation, with each tablet containing 
gemiﬂ  oxacin mesylate equivalent to 320 mg of gemiﬂ  oxacin 
(Hong 2001).
Mechanism of action and resistance
Gemiﬂ  oxacin possesses a strong afﬁ  nity for topoisomerase 
IV, which is likely to be responsible for its potent in vitro 
activity against S. pneumoniae (Morrissey and George 2000). 
It is a dual targeting quinolone and retains activity against 
mutations in either or both targets (Heaton et al 2000; Gil-
lespie et al 2002; Yague et al 2002). The high afﬁ  nity for 
CAP diagnosis
Mild-Moderate Moderate-Severe
Amoxicillin
Macrolide
Disease Severity
Risk factor 
β-lactam-betalactamase inhibitor
±
Macrolide
New generation fluoroquinolone
No Yes
β-lactam-betalactamase inhibitor /
Broad spectrum cephalosporin
±
Macrolide
New generation fluoroquinolone
Site of management  Outpatient Inpatient
Figure 2 Algorithm for the selection of empirical antimicrobial agent in CAP.Therapeutics and Clinical Risk Management 2007:3(3) 445
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gemiﬂ  oxacin for both targets accounts for its high potency 
and continued activity. 
Organisms with a single mutation in the ParC subunit 
usually remain susceptible to these agents. S. pneumoniae 
becomes resistant to gemiﬂ  oxacin through mutations in gyrA. 
Because mutations in parC arise at a much higher rate than 
in gyrA in S. pneumoniae, resistance to gemiﬂ  oxacin may 
be expected to emerge at a slower rate than for quinolones 
that become resistant through mutations in parC (Gillespie 
et al 2003). In fact, despite a variety of resistance mecha-
nisms, quinolone-resistant strains of S. pneumoniae remain 
susceptible to gemiﬂ  oxacin (Heaton et al 1999; Broskey et 
al 2000). 
Gemiﬂ  oxacin was also shown to have a signiﬁ  cant in 
vitro post-antibiotic effect against strains of S. pneumoniae 
and H. inﬂ  uenzae (Davies et al 2000a). In another study, the 
PAE at 4 x MIC was greater than 6 hours for H. inﬂ  uenzae, 
Pseudomonas aeruginosa, and Proteus vulgaris and 0.1–2.5 
hours for the other Gram-positive and Gram-negative organ-
isms tested (Davies et al 2000b).
In vitro activity
Compared with other quinolones, it possesses enhanced 
in vitro activity against S. pneumoniae, including isolates 
resistant to β-lactams, macrolides, and quinolones, while 
retaining activity against Gram-negative and atypical 
pathogens. The in vitro activity of gemiﬂ  oxacin, compared 
to other quinolones, against commonly isolated respiratory 
pathogens is shown in Table 2 (Deshpande and Jones 2000; 
Marchese et al 2000; McCloskey et al 2000; File and Tillot-
son 2004; Oncu et al 2004; Bhavnani and Andes 2005). 
Pharmacokinetic and  pharmacodynamic properties
Gemiﬂ  oxacin given orally is rapidly absorbed, with the peak 
concentration being observed in 30–120 minutes, and it is 
widely distributed throughout the body (2004). Compared 
with other quinolones, gemiﬂ  oxacin achieves higher con-
centrations in bronchial mucosa, epithelial lining ﬂ  uid, and 
bronchoalveolar macrophages than in plasma (Appelbaum 
et al 2004; Bhavnani and Andes 2005). It has also the high-
est area-under-the-curve (AUC)/MIC and Cmax/MIC values 
among quinolones (Firsov et al 2000). 
Gemiﬂ  oxacin and its metabolites are dually excreted via 
urine and feces. Approximately 20%–30% of the adminis-
tered dose is excreted unchanged in the urine, and the plasma 
half-life is approximately 6–8 hours (Allen et al 2001; Zhanel 
and Noreddin 2001). Dosage adjustments are not necessary in 
patients with mild renal or any level of hepatic insufﬁ  ciency, 
nor in the elderly.
Drug–drug interactions
Gemiﬂ  oxacin has been investigated for interactions with vari-
ous other substances (File and Tillotson 2004). Gemiﬂ  oxacin 
can be taken with or without food, should be taken either 2 
hours before sucralfate or ferrous sulfate, or at least 3 hours 
after ferrous sulfate, and should be administered 2 hours 
or more prior to or 3 hours or more after cation-containing 
compounds (Allen et al 1999, 2000a, b).
Adverse effects
The most frequently reported adverse effects in the clinical 
trials were diarrhea, nausea, and rash (File et al 2001; File 
and Tillotson 2004). The potential of phototoxicity caused 
by gemiﬂ  oxacin is similar to that of ciproﬂ  oxacin (Allen 
et al 1999). Gemiﬂ  oxacin has been reported to demonstrate 
small, non-signiﬁ  cant QTs interval prolongation (Yoo et al 
2004). Liver failure does not appear to be associated with 
gemiﬂ  oxacin, but mild and reversible elevations of liver 
enzymes may occur (Lode et al 2002). 
On the whole, the following advantages are more promi-
nent in gemiﬂ  oxacin compared with other drugs usable in 
CAP (Ball 2000; File and Tillotson 2004):
•  Enhanced activity against S. pneumoniae (including 
PRSP)
•  Improved activity against atypical pathogens
•  Active against Gram-negative pathogens except P. ae-
ruginosa
Table 2 The MIC90 (µg/mL) values of gemiﬂ  oxacin and other quinolones against common CAP pathogens
Microorganism Gemiﬂ  oxacin  Levoﬂ  oxacin  Gatiﬂ  oxacin  Moxiﬂ  oxacin  Ciproﬂ  oxacin
S. pneumoniae 0.015–0.06  1–2  0.50 0.12–0.25  1–4
H. inﬂ  uenzae <0.004–0.06  0.015–0.12  0.015–0.03  <0.03–0.06  0.008–0.03
M. catarrhalis 0.008–0.03  <0.03–0.06  <0.03–0.03  0.03–0.125  <0.016–<0.5
M. pneumoniae 0.125  0.5  0.125 0.125  2
C. pneumoniae 0.25  1  0.25 1  2
L. pneumophila 0.016  0.016  0.016  0.016 0.03Therapeutics and Clinical Risk Management 2007:3(3) 446
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•  Favorable pharmacokinetics, once-daily dosing, balanced 
elimination requiring very little dosage modiﬁ  cations
•  Based on pharmacokinetics, highly effective in respira-
tory infections
•  Few drug–drug interaction
•  Few adverse drug reactions
Clinical experience of gemiﬂ  oxacin in CAP
Six clinical trials of gemiﬂ  oxacin have been performed in CAP 
(Ball et al 2001; File et al 2001; Lode et al 2002; Appelbaum et 
al 2004; Leophonte et al 2004). The clinical success rates were 
all close to or above 90% for gemiﬂ  oxacin (87.6%–94.0%) 
and were similar to the comparators (87.6%–93.4%). Also, 
bacteriological success rate with gemiﬂ  oxacin was good in all 
six studies (87.2%–90.6%) and comparable with that recorded 
by the comparators in the four comparative studies (88.9%–
89.3%). Table 3 summarizes the clinical and bacteriological 
efﬁ  cacy of gemiﬂ  oxacin and comparator agents. 
Conclusion
CAP remains a frequent and important clinical entity. Nearly 
80% of the treatment for this condition is provided in the 
outpatient setting. Antimicrobial treatment of CAP must 
cover S. pneumoniae, H. inﬂ  uenzae, and M. catarrhalis and 
in many circumstances should also cover the intracellular 
atypical pathogens. The β-lactams have been considered 
standard therapy for the treatment of CAP. However, rising 
resistance rates among CAP pathogens are now a primary 
concern. Recent antibiotic usage and the presence of co-
morbidities are among the accepted risk factors for CAP 
caused by resistant pathogens. Patients without any risk 
factor should be treated effectively with a narrow spectrum 
β-lactam agent, like amoxicillin, or a macrolide. For patients 
with risk factors broader-spectrum β-lactam agents and a 
macrolide or a new generation of quinolones should be started 
empirically. Quinolones are broad-spectrum antibiotics that 
exhibit high levels of penetration into the lungs and low levels 
of resistance. Gemiﬂ  oxacin is a new quinolone antibiotic 
that targets pneumococcal DNA gyrase and topoisomerase 
IV and is highly active against S. pneumoniae including 
penicillin-, macrolide-, and quinolone-resistant strains, as 
well as H. inﬂ  uenzae and the atypical pathogens. Among 
the quinolones, it has the best in vitro activity. In clinical 
trials in CAP, gemiﬂ  oxacin has been shown to be as effec-
tive as the comparators and demonstrates an adverse event 
proﬁ  le that is in line with comparator agents. Its improved 
bioavailability, pharmacokinetic–pharmacodynamic proper-
ties, and safety proﬁ  le make this agent an excellent option 
for the treatment of CAP. But it should be kept in mind that 
unnecessary use of these agents will facilitate the emergence 
of resistant strains. 
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